Crawford Investment Counsel’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $95.3M | Sell |
486,433
-10,066
| -2% | -$1.96M | 1.63% | 20 |
|
|
2025
Q4 | $86.2M | Buy |
496,499
+2,067
| +0.4% | +$376K | 1.43% | 25 |
|
|
2025
Q3 | $94.2M | Buy |
494,432
+9,473
| +2% | +$1.68M | 1.56% | 22 |
|
|
2025
Q2 | $87.1M | Sell |
484,959
-14,221
| -3% | -$2.47M | 1.52% | 25 |
|
|
2025
Q1 | $84.5M | Sell |
499,180
-14,779
| -3% | -$2.43M | 1.5% | 25 |
|
|
2024
Q4 | $77.5M | Buy |
513,959
+6,402
| +1% | +$996K | 1.39% | 30 |
|
|
2024
Q3 | $78.8M | Buy |
507,557
+6,210
| +1% | +$927K | 1.35% | 29 |
|
|
2024
Q2 | $68.6M | Buy |
501,347
+83,985
| +20% | +$11.5M | 1.31% | 29 |
|
|
2024
Q1 | $55.6M | Buy |
+417,362
| New | +$54.2M | 1.03% | 37 |
|
|
2018
Q3 | – | Sell |
-1,880
| Closed | -$207K | – | 261 |
|
|
2018
Q2 | $207K | Sell |
1,880
-115
| -6% | -$12K | 0.01% | 251 |
|
|
2018
Q1 | $200K | Buy |
+1,995
| New | +$204K | 0.01% | 253 |
|
|
2017
Q4 | – | Sell |
-2,165
| Closed | -$203K | – | 256 |
|
|
2017
Q3 | $203K | Sell |
2,165
-2,760
| -56% | -$293K | 0.01% | 239 |
|
|
2017
Q2 | $547K | Sell |
4,925
-6,120
| -55% | -$647K | 0.02% | 186 |
|
|
2017
Q1 | $1.08M | Sell |
11,045
-498,175
| -98% | -$47.5M | 0.04% | 154 |
|
|
2016
Q4 | $46.8M | Sell |
509,220
-17,884
| -3% | -$1.54M | 1.7% | 24 |
|
|
2016
Q3 | $44.6M | Sell |
527,104
-11,156
| -2% | -$937K | 1.63% | 24 |
|
|
2016
Q2 | $43.8M | Sell |
538,260
-11,971
| -2% | -$912K | 1.74% | 26 |
|
|
2016
Q1 | $39.3M | Sell |
550,231
-10,362
| -2% | -$695K | 1.65% | 31 |
|
|
2015
Q4 | $39.9M | Sell |
560,593
-178,843
| -24% | -$12M | 1.76% | 27 |
|
|
2015
Q3 | $45.5M | Sell |
739,436
-33,774
| -4% | -$2.36M | 1.98% | 29 |
|
|
2015
Q2 | $56.1M | Buy |
773,210
+654,910
| +554% | +$48.4M | 2.13% | 28 |
|
|
2015
Q1 | $9.09M | Sell |
118,300
-60
| -0.1% | -$4.3K | 0.33% | 48 |
|
|
2014
Q4 | $7.94M | Buy |
118,360
+1,780
| +2% | +$112K | 0.28% | 54 |
|
|
2014
Q3 | $7.07M | Hold |
116,580
| – | – | 0.26% | 53 |
|
|
2014
Q2 | $6.84M | Sell |
116,580
-28,930
| -20% | -$1.69M | 0.24% | 47 |
|
|
2014
Q1 | $8.43M | Buy |
145,510
+28,970
| +25% | +$1.55M | 0.31% | 44 |
|
|
2013
Q4 | $6.24M | Buy |
116,540
+40
| +0% | +$2.37K | 0.23% | 49 |
|
|
2013
Q3 | $7.2M | Buy |
116,500
+1,000
| +0.9% | +$59.9K | 0.29% | 47 |
|
|
2013
Q2 | $7M | Buy |
+115,500
| New | +$6.88M | 0.29% | 48 |
|
Other funds holding DGX
VCM
VPM
EIG
Crawford Investment Counsel's DGX Position: Q1 2026 in Review
Crawford Investment Counsel reduced its Quest Diagnostics (DGX) stake by 2% in Q1 2026, selling an estimated $1.96M and leaving 486,433 shares worth $95.3M. The position accounts for 1.63% of the portfolio, ranked #20.
Crawford Investment Counsel first reported a position in DGX in Q2 2013 and has held it in 29 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Crawford Investment Counsel held 486,433 shares of Quest Diagnostics worth $95.3M as of Q1 2026.
- Crawford Investment Counsel sold 10,066 Quest Diagnostics shares in Q1 2026, an estimated $1.96M.
- Quest Diagnostics made up 1.63% of Crawford Investment Counsel's portfolio in Q1 2026, its #20 holding.
- Crawford Investment Counsel first reported a position in Quest Diagnostics in Q2 2013 and has held it in 29 quarters since.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Crawford Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.